Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $554.32M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 2.66M
Average 3.76M
SANA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Sana Biotechnology, Inc.NASDAQ: SANA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $11.46M fell 0.2% year over year, ahead of the -25.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 5.9% from the prior quarter. Over 3 fiscal years it compounded at -14.8% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -30.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $11.46M-5.9% QoQ
- Last fiscal yearDec 2025
- $44.3M-30.8% YoY
- LTMMar 2026
- $44.27M-25.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.2% | -100.0% | -99.8 pp |
| 1 year | -30.8% | -100.0% | -69.2 pp |
| 3-year CAGR | -14.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 44.3M USD
- Year-over-year change
- -30.8%
- 4-year CAGR
- -3.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.3M | -30.8% |
| FY2024 | 2024-12-31 | 64.04M | -12.6% |
| FY2023 | 2023-12-31 | 73.3M | +2.4% |
| FY2022 | 2022-12-31 | 71.56M | +42.0% |
| FY2021 | 2021-12-31 | 50.41M | — |
Selling, General & Admin vs competitors
How SANA compares with its peers on the latest reported figures
- SANA's LTM Mar 2026 selling, general & admin of $44.27M is the 7th highest of the 11 companies compared; the peer median is $54.08M.
- Its year-over-year change of -25.3% is the 8th highest of 11, against a peer median of -8.6%.
- Over three fiscal years its annual growth of -14.8% compares with a peer median of -8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $357.49M | +10.5% | +25.2% | 26.3% | |
| LTM Mar 2026 | $157.94M | +14.5% | +9.9% | 239.0% | |
| LTM Jun 2026 | $125.4M | +14.0% | +9.0% | 80.4% | |
| LTM Sep 2026 | $68.9M | -6.0% | -10.5% | 273.7% | |
| LTM Mar 2026 | $55.88M | -11.2% | -10.5% | — | |
| LTM Mar 2026 | $52.28M | -5.2% | +10.5% | — | |
| LTM Mar 2026 | $44.27M | -25.3% | -14.8% | — | |
| LTM Mar 2026 | $42.34M | -49.3% | -18.0% | 670.4% | |
| LTM Mar 2026 | $30.49M | -13.9% | -7.9% | 67.6% | |
| LTM Mar 2026 | $22.18M | -32.4% | -9.0% | — | |
| LTM Mar 2026 | $17.8M | -55.8% | -27.2% | 76.9% | |
| Peer median (excluding SANA) | $54.08M | -8.6% | -8.5% | 80.4% | |
Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 12.75M |
| Gross Profit | 0 | 0 | 0 | 0 | (12.75M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 306.5M | 201M | 219.84M | 208.68M | 131.98M |
| Selling, General & Admin | 50.41M | 71.56M | 73.3M | 64.04M | 44.3M |
| Operating Expenses | 356.91M | 272.56M | 293.14M | 272.72M | 178.21M |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| EBITDA | (344.86M) | (253.85M) | (258.7M) | (249.37M) | (231.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (356.91M) | (272.56M) | (293.14M) | (272.72M) | (190.96M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 676K | 3.76M | 9.94M | 10.47M | 3.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 981K | 3.09M | 9.89M | 5.96M | (53.21M) |
| Income Before Tax | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| EPS (Diluted) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| Weighted Avg Shares | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
| Weighted Avg Shares (Diluted) | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.